LivaNova (LIVN) AI Stock Analysis

• Market Cap: $2.91B
• Dividend Yield: N/A
• Average Volume (3M): 485.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 8.57%
• EPS Growth: -1154.64%
• Country: US
• Employees: 2,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.05
• Shares Outstanding: 54,601,074
• 10 Day Avg. Volume: 421,110
• 30 Day Avg. Volume: 485,312
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 1.80
• Enterprise Value/Gross Profit: 2.60
• Enterprise Value/Ebitda: -32.14
• 1Y Price Target: $63.14
• Price Target Upside: 17.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 55 Neutral
• Price Target: $54.00 ▲(0.26% Upside)

LivaNova's overall score is driven by strong earnings call results, showcasing significant revenue growth and clinical achievements. However, financial performance is hindered by profitability challenges and valuation concerns due to a negative P/E ratio. Technical analysis provides mixed signals, with no clear trend direction.

Positive Factors

Revenue Growth

The 10% organic revenue growth indicates strong demand and effective market penetration, particularly in cardiopulmonary and neuromodulation sectors, supporting long-term financial stability.

Clinical Milestones

Significant clinical milestones, such as seizure reduction in VNS therapy, enhance product credibility and can drive adoption, positively impacting long-term growth.

Debt Reduction

Reducing debt levels improves financial health and flexibility, enabling LivaNova to invest in growth opportunities and withstand economic fluctuations.

Negative Factors

Profitability Challenges

Persistent profitability challenges with negative margins indicate operational inefficiencies, which could hinder reinvestment and growth capabilities over time.

Supply Chain Constraints

Supply chain constraints could limit production capacity and slow market expansion, potentially affecting revenue growth and market share in the long term.

Tax Rate Increase

An increasing tax rate reduces net income, impacting cash flow and the ability to fund strategic initiatives, potentially affecting long-term profitability.

LivaNova Business Overview & Revenue Model

Company Description

LivaNova (LIVN) is a global medical technology company focused on developing innovative therapies for patients suffering from severe neurological and cardiovascular conditions. The company operates primarily in two sectors: cardiovascular and neuromodulation. LivaNova's core products include advanced cardiac surgery devices, neuromodulation devices for epilepsy treatment, and various other therapeutic solutions aimed at improving patient outcomes and enhancing surgical procedures.

How the Company Makes Money

LivaNova generates revenue through the sale of its medical devices and related services. The company has key revenue streams from its cardiovascular segment, which includes products such as heart-lung machines, perfusion products, and cardiac surgery devices. The neuromodulation segment contributes significantly to its earnings through the sale of devices designed for epilepsy treatment and other neurological disorders. Additionally, LivaNova benefits from ongoing partnerships with healthcare providers and institutions that utilize its technologies. The company also engages in research and development initiatives, which may lead to new product launches and expanded market opportunities, further enhancing its revenue potential.

LivaNova Financial Statement Overview

Summary

LivaNova shows moderate revenue growth but struggles with profitability, as indicated by negative net income and EBIT margins. The balance sheet is stable with manageable leverage, yet inefficiencies are evident with a negative return on equity. Cash flow performance is improving, particularly in free cash flow growth, but operational cash generation remains a concern.

Income Statement

LivaNova's income statement shows moderate revenue growth with a 2.66% increase in TTM. However, the company is struggling with profitability, as indicated by a negative net profit margin of -16.14% and a negative EBIT margin of -9.33%. The gross profit margin remains strong at 69.07%, but the negative EBITDA margin of -5.59% highlights operational challenges.

Balance Sheet

The balance sheet reflects a stable equity position with a debt-to-equity ratio of 0.42, indicating manageable leverage. However, the return on equity is negative at -17.66%, suggesting inefficiencies in generating returns from equity. The equity ratio stands at 44.80%, showing a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals a positive trend with an 11.39% growth in free cash flow. The operating cash flow to net income ratio is 0.26, indicating some cash generation challenges relative to net income. However, the free cash flow to net income ratio of 0.75 suggests better cash flow management compared to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.31B	1.25B	1.15B	1.02B	1.04B	934.20M
Gross Profit	904.33M	870.87M	771.25M	707.20M	706.00M	618.20M
EBITDA	-73.18M	202.52M	39.02M	30.85M	-6.33M	-225.87M
Net Income	-211.32M	63.23M	17.55M	-86.20M	-135.70M	-343.30M
Balance Sheet
Total Assets	2.51B	2.51B	2.43B	2.29B	2.20B	2.41B
Cash, Cash Equivalents and Short-Term Investments	593.64M	428.86M	266.50M	214.20M	208.00M	252.80M
Total Debt	473.40M	676.77M	640.40M	571.00M	275.40M	697.80M
Total Liabilities	1.38B	1.19B	1.15B	1.09B	906.40M	1.29B
Stockholders Equity	1.12B	1.32B	1.28B	1.21B	1.29B	1.12B
Cash Flow
Free Cash Flow	162.10M	135.93M	39.93M	43.40M	77.00M	-114.40M
Operating Cash Flow	216.59M	183.04M	74.91M	69.90M	102.50M	-79.40M
Investing Cash Flow	-48.82M	-48.16M	-40.33M	-38.40M	36.90M	-41.80M
Financing Cash Flow	-220.13M	18.55M	21.48M	280.10M	-181.50M	310.80M

LivaNova Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 53.86
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LIVN, the sentiment is Neutral. The current price of 53.86 is above the 20-day moving average (MA) of 53.15, below the 50-day MA of 54.50, and above the 200-day MA of 46.25, indicating a neutral trend. The MACD of 0.27 indicates Negative momentum. The RSI at 51.10 is Neutral, neither overbought nor oversold. The STOCH value of 62.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LIVN.

LivaNova Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TMDX	―	$4.42B	67.08	28.21%	―	48.09%	2410.18%
UFPT	―	$1.46B	21.95	19.29%	―	40.98%	34.80%
INSP	―	$2.22B	43.55	8.07%	―	22.05%	785.52%
ITGR	―	$2.29B	27.34	5.18%	―	7.81%	-26.32%
LIVN	―	$2.91B	-13.70	-17.87%	―	8.57%	-1154.64%
AORT	―	$2.12B	-104.68	-5.01%	―	7.44%	-109.83%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

LivaNova Corporate Events

LivaNova Appoints Donald Zurbay to Board of Directors

On September 3, 2025, LivaNova PLC appointed Donald Zurbay to its Board of Directors and as a member of the Audit and Compliance Committee, effective September 4, 2025. Mr. Zurbay brings extensive experience from his leadership roles at Patterson Companies and St. Jude Medical, enhancing LivaNova’s strategic direction and governance.

The most recent analyst rating on (LIVN) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on LivaNova stock, see the LIVN Stock Forecast page.

LivaNova PLC Reports Strong Q2 Earnings and Raised Guidance

LivaNova PLC’s recent earnings call exuded a positive sentiment, underscored by robust financial performance and clinical advancements. The company reported significant revenue growth, particularly in its epilepsy and cardiopulmonary segments, despite facing supply chain challenges and transitional issues in neuromodulation. Overall, the sentiment was buoyant, driven by strong financial results and an optimistic outlook.

LivaNova PLC Reports Strong Q2 2025 Results

LivaNova PLC is a global medical technology company specializing in innovative solutions for neurological and cardiac conditions, with a strong presence in over 100 countries. In its latest earnings report, LivaNova announced a robust performance for the second quarter of 2025, marked by significant revenue growth and an upward revision of its full-year guidance. The company reported a 10.7% increase in revenue, reaching $352.5 million, and a notable rise in adjusted earnings per share to $1.05. LivaNova also initiated a process with the U.S. Centers for Medicare and Medicaid Services to reconsider national coverage for its VNS Therapy for treatment-resistant depression, highlighting its strategic focus on expanding its neuromodulation capabilities. Looking ahead, LivaNova has raised its full-year 2025 revenue growth expectations, projecting an 8.0% to 9.0% increase on a constant-currency basis, reflecting confidence in its continued market leadership and commitment to delivering life-changing therapies.